statement
CagriSema is a fixed-dose combination formulation.
A statement by 界面新闻. Statements are as reported by the cited publishers — not verified by DecisionGateway.
该药是一款固定剂量复方制剂
Related claims
CagriSema is injected subcutaneously once weekly.界面新闻 · statementCagriSema consists of the long-acting amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.界面新闻 · statementNovo Nordisk announced that the marketing application for its new drug CagriSema (cagrilintide and semaglutide injection) for long-term weight management has been accepted by the National Medical Products Administration.诺和诺德 · statementThe 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.report author · statementЭтим препаратам нет аналога.Голикова · statementThis company has officially released its enterprise core AI product.电报解读 · statement